Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality TestingInvivoscribe Marketing2021-02-17T18:10:07-08:00November 17th, 2020|2020 Publications, Featured Publications, Publications| Read more
Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple MyelomaInvivoscribe Marketing2021-02-11T21:50:38-08:00May 1st, 2020|2020 Publications, Publications| Read more
Monitoring minimal residual disease in the bone marrow using next generation sequencingInvivoscribe Marketing2021-02-11T22:00:56-08:00January 17th, 2020|2020 Publications, Publications| Read more
A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutationsInvivoscribe Marketing2021-02-11T23:49:39-08:00August 25th, 2018|2018 Publications, Featured Publications, Publications| Read more
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALLInvivoscribe Marketing2021-02-11T23:54:51-08:00August 22nd, 2018|2018 Publications, Featured Publications, Publications| Read more
Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Softwarewmm2021-02-26T19:12:40-08:00November 7th, 2017|2017 Press Releases, Press Releases| Read more
Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)Invivoscribe Marketing2021-02-12T00:14:15-08:00August 9th, 2017|2017 Publications, Publications| Read more
Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Softwarewmm2021-02-26T19:13:58-08:00February 28th, 2017|2017 Press Releases, Press Releases| Read more